
Researchers have shown that a new drug, Alirocumab, can cut back the "bad" cholesterol to the level of a baby.
According to the Daily Express, Alirocumab is being hailed as the latest weapon against heart attacks and stroke, after a study of more than 2,000 patients found that it eliminated dangerous blood fats in more than a third of people taking statins.
Advertisement
Lead researcher Professor Kausik Ray said that around 40 percent of people who took it saw their levels reduce to that of a newborn, and the medication is being referred to as the Pac-Man drug because, as it "gobbles up" a protein and allows the body to get free of bad cholesterol.
Amongst the 2,338 patients who took part in the trial, 788 were given a placebo and 1,550 Alirocumab and a statin, where of the 1,550, 562 saw their level of bad cholesterol fall to less than a baby's level within a year.
Statins can reduce LDL cholesterol by up to 50 percent and this drug reduced it by a further 50 per cent.
Prof. Ray said that it was the biggest reduction they had since statins were introduced, and though it was likely to reduce the risk of heart disease, the risk wouldn't be eliminated.
Source: ANI
Advertisement
Statins can reduce LDL cholesterol by up to 50 percent and this drug reduced it by a further 50 per cent.
Prof. Ray said that it was the biggest reduction they had since statins were introduced, and though it was likely to reduce the risk of heart disease, the risk wouldn't be eliminated.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News

Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.

By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.

Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.

Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.

Memory deficits in individuals with epilepsy, especially cognitive difficulties, might partially stem from the transient impairments caused by these slow waves.